ライフサイエンスコーパス: paroxysmal

1 n limited areas (persistent 2.5+/-1.7 versus paroxysmal 1.7+/-0.5 cm(2); P=0.30).

2 Patients had highly symptomatic AF (78% paroxysmal, 22% early persistent) and experienced failur

3 all, all-cause mortality also was lower with paroxysmal (3.0%/year) compared with persistent (4.4%/ye

4 ; mean left atrial diameter, 43+/-5 mm) with paroxysmal (36 of 50 patients; 72%) or short-standing (<

5 trium diameter, 45+/-6 mm) with a history of paroxysmal (40/66, 61%) or persistent atrial fibrillatio

6 ulants were used less often in patients with paroxysmal (53%) and new onset (16%) AF than in patients

7 tive patients (mean age, 61+/-10 years) with paroxysmal (550) or persistent atrial fibrillation (583)

8 +/-11 years) undergoing catheter ablation of paroxysmal (59%) or persistent (41%) AF, the ACE inserti

9 esides the 15-year-old patient complained of paroxysmal abdominal pains.

10 During a seizure, paroxysmal activity is not restricted to the EZ, but may

11 bolic event was lower in those patients with paroxysmal AF (1.49%/year), compared with persistent (1.

12 tients with persistent AF than in those with paroxysmal AF (41.1 +/- 28.0 vs. 33.2 +/- 22.8, p = 0.04

13 METHODS AND In 86 patients with paroxysmal AF (43 with >/=moderate OSA [apnea-hypopnea i

14 malities (cryptogenic 37% vs 45%; p=0.18) or paroxysmal AF (6% vs 10%; p=0.17) at baseline or of new

15 Compared with patients with paroxysmal AF (60% of cohort), those with persistent AF

16 which 226 (74%) were confined to symptomatic paroxysmal AF (average, 5+/-5; range, 1 to >20), whereas

17 - 10 years, 186 males) randomized those with paroxysmal AF (n = 115) to CPVI or HFSA-only (noninferio

18 ecutively enrolled patients with symptomatic paroxysmal AF (n = 579) or persistent AF.

19 permanent (N=4449), persistent (N=4237), and paroxysmal AF (N=4219).

20 al [CI], 1.89-3.60), 2.1-fold higher odds of paroxysmal AF (odds ratio, 2.14; 95% CI, 1.45-3.16) and,

21 fold higher odds of persistent compared with paroxysmal AF (odds ratio, 2.19; 95% CI, 1.66-2.88).

22 y AF (OR = 2.07, 95% CI 1.59-2.68), and with paroxysmal AF (OR = 1.98, 95% CI 1.44-2.74) and chronic

23 rcoplasmic reticulum Ca2+ -release events in paroxysmal AF (pAF) are unknown.

24 on (E169K) in 2 patients with juvenile-onset paroxysmal AF (pAF).

25 ex for AF patients was 0.6 +/- 0.5 mm Hg/mL (paroxysmal AF 0.51 +/- 0.4 and persistent AF 0.73 +/- 0.

26 Sensitivity analysis of 398 paroxysmal AF ablation procedures showed no incremental

27 Transformation to paroxysmal AF after initial ablation may be a step towar

28 xt below) over 12 weeks in 134 patients with paroxysmal AF and implanted pacemakers where AF burden (

29 d at preferred sites in 10% of patients with paroxysmal AF and in 35% of patients with persistent AF.

30 g recurrences of AF in younger patients with paroxysmal AF and mild structural heart disease.

31 In comparison, control patients with paroxysmal AF and OSA who underwent PV isolation alone w

32 rate, including AF triggers in patients with paroxysmal AF and OSA.

33 Patients with documented symptomatic paroxysmal AF and previously failed therapy with >/= 1 m

34 g-term single procedure success rates in non-paroxysmal AF are disappointingly low for current stepwi

35 ocardiographic abnormalities and subclinical paroxysmal AF at baseline in patients with index events

36 ared with patients without AF, patients with paroxysmal AF at randomization had a higher risk of the

37 ange 0-12.8) and was higher in patients with paroxysmal AF compared with patients without a history o

38 %) developed permanent AF, preceded by 7+/-6 paroxysmal AF episodes.

39 442 (69%) males and 328 (51%) patients with paroxysmal AF equally distributed between the 2 groups.

40 Long-term recurrences (n=171) were paroxysmal AF in 48 patients (28%) and persistent AF/atr

41 a potential molecular mechanism involved in paroxysmal AF pathogenesis.

42 A total of 513 paroxysmal AF patients (age 54+/-11 years, 73% males) un

43 he substrate occurs and is more effective in paroxysmal AF rather than persistent or permanent AF.

44 In ENGAGE AF-TIMI 48 trial, patients with paroxysmal AF suffered fewer thromboembolic events and d

45 cantly worse in patients with persistent and paroxysmal AF than in controls (Repeatable Battery for t

46 ient participants with confirmed symptomatic paroxysmal AF that required cardioversion (n = 428), at

47 (STOP AF) trial randomized 245 patients with paroxysmal AF to medical therapy versus cryoballoon-base

48 In patients with paroxysmal AF undergoing extended PV antrum isolation, t

49 Patients with paroxysmal AF underwent pulmonary vein isolation.

50 HF patients with a history of AF, those with paroxysmal AF were at greater risk of HF hospitalization

51 Patients with drug-refractory paroxysmal AF were enrolled in a multicenter, randomized

52 /= 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use

53 involving 127 treatment-naive patients with paroxysmal AF were randomized at 16 centers in Europe an

54 152 patients undergoing de novo ablation for paroxysmal AF were randomized to 2 different treatment a

55 Patients with drug-refractory, symptomatic paroxysmal AF were randomly assigned to either incomplet

56 miR-25 were lower in atria of patients with paroxysmal AF when compared with patients in sinus rhyth

57 Patients with paroxysmal AF who presented for AF ablation were randomi

58 f 291 hypertensive patients with symptomatic paroxysmal AF who were scheduled to undergo pulmonary ve

59 ost study enrolled patients with symptomatic paroxysmal AF with an initial 3-month noninterventional

60 Among patients with paroxysmal AF without previous antiarrhythmic drug treat

61 PV antrum isolation (paroxysmal AF) and posterior wall isolation with complex

62 tal of 152 patients (age, 60+/-11 years; 63% paroxysmal AF) undergoing PV isolation for AF were studi

63 56.9 +/- 11.8 years, 63.9% male, 69.2% with paroxysmal AF) who were arrhythmia-free at 12 months (ex

64 59.1 [10.7] years, 31.5% female, 64.6% with paroxysmal AF).

65 with hypertrophic cardiomyopathy and AF (28% paroxysmal AF).

66 group 1: two events (0.87%) in patients with paroxysmal AF, 4 (2.3%) in patients with persistent AF,

67 In 31 patients (12 persistent AF, 15 paroxysmal AF, 4 controls with no AF), we recorded left

68 of SCI was present in 80 patients (89%) with paroxysmal AF, 83 (92%) with persistent AF (paroxysmal v

69 are those with normal structural hearts and paroxysmal AF, although those with congestive heart fail

70 ernans was more prevalent in persistent than paroxysmal AF, and absent in controls (P=0.018 APD; P=0.

71 r the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrhythmic drug

72 In paroxysmal AF, HFSA failed to achieve noninferiority at

73 In paroxysmal AF, HFSA failed to achieve noninferiority at

74 longer AF duration, with more prevalent non-paroxysmal AF, higher CHADS2/CHA2DS2-VASc score, and ora

75 approach generally agreed on for those with paroxysmal AF, optimal techniques for the ablation of no

76 35% and 10% of patients with persistent and paroxysmal AF, respectively.

77 rotein is elevated in atria of patients with paroxysmal AF, suggesting that microRNA-mediated post-tr

78 st rate-dependent amplification, followed by paroxysmal AF, with marked rate dependence, and undetect

79 In patients with paroxysmal AF, yoga improves symptoms, arrhythmia burden

80 oved noninferior to RFA for the treatment of paroxysmal AF.

81 not significantly affected in subjects with paroxysmal AF.

82 ases inflammatory cytokines in patients with paroxysmal AF.

83 n of recurrence in patients with symptomatic paroxysmal AF.

84 jection fraction 61 +/- 6%) with symptomatic paroxysmal AF.

85 ent recording, 30 (7.4%) were diagnosed with paroxysmal AF.

86 ndomization, and of these, 1,645 (30.0%) had paroxysmal AF.

87 y bypass surgery of whom 13 had a history of paroxysmal AF.

88 AF/AT after TAVR, 30.2% had newly diagnosed paroxysmal AF/AT before the procedure.

89 ng catheter ablation for symptomatic AF (66% paroxysmal AF; age, 58+/-10 years; left atrial area, 27+

90 ulation (N=2069; 66% men; 60+/-10 years; 62% paroxysmal AF; mean CHADS2, 1.2+/-0.9; CHA2DS2-VASc, 2.1

91 cts were enrolled: 180 patients with AF (50% paroxysmal and 50% persistent) and 90 controls.

92 However, AF can be paroxysmal and asymptomatic, thereby making detection wi

93 role in the pathophysiology and treatment of paroxysmal and chronic patients with AF is unknown.

94 rogression from spontaneous atrial ectopy to paroxysmal and eventually long-lasting AF.

95 onal cohort study of patients diagnosed with paroxysmal and persistent AF (undergoing their first cat

96 Patients with paroxysmal and persistent AF had a higher prevalence and

97 The relationship among paroxysmal and persistent AF, SCI, and cognitive impairm

98 similar risk for symptomatic stroke in both paroxysmal and persistent AF.

99 ) and cognitive performance in patients with paroxysmal and persistent atrial fibrillation (AF) and c

100 enance of sinus rhythm in patients with both paroxysmal and persistent atrial fibrillation.

101 l FIRM-guided ablation procedures (n=24; 50% paroxysmal) at University of California, Los Angeles Med

102 Transformation from persistent to paroxysmal atrial fibrillation (AF) after ablation sugge

103 Maintenance of paroxysmal atrial fibrillation (AF) by fast rotors in th

104 Patients with paroxysmal atrial fibrillation (AF) eligible for AAD the

105 e of pulmonary vein (PV) antrum isolation in paroxysmal atrial fibrillation (AF) patients over more t

106 cts with symptomatic, persistent/high-burden paroxysmal atrial fibrillation (AF) were enrolled at 6 c

107 stantial number of arrhythmia recurrences in paroxysmal atrial fibrillation (AF).

108 lmonary vein (PV) isolation in patients with paroxysmal atrial fibrillation (AF).

109 c perturbations frequently antecede onset of paroxysmal atrial fibrillation (AF).

110 ein (PV) activity has been shown to maintain paroxysmal atrial fibrillation (AF).

111 atrial activation as seen clinically during paroxysmal atrial fibrillation (AF).

112 observed in 70 patients (16.1%) before TAVR: paroxysmal atrial fibrillation (AF)/atrial tachycardia (

113 lloon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation (MACPAF) study, serial 3-

114 Thirty-seven patients with paroxysmal atrial fibrillation (median age, 63.0 [interq

115 line within 5 years (odds ratio [OR]: 12.7), paroxysmal atrial fibrillation (OR: 5.19), subtherapeuti

116 The associations of paroxysmal atrial fibrillation (PAF) and persistent atri

117 t the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its

118 atients; 60 patients undergoing ablation for paroxysmal atrial fibrillation (PAF), 30 patients underg

119 heter ablation is important for treatment of paroxysmal atrial fibrillation (PAF).

120 n PVI or GP ablation alone, in patients with paroxysmal atrial fibrillation (PAF).

121 g persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial si

122 CH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using sh

123 The Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial randomize

124 ustained ventricular tachycardia [n=1], fast paroxysmal atrial fibrillation [n=1], symptomatic bradyc

125 nt Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978).

126 on and find out whether it could improve the paroxysmal atrial fibrillation ablation results in human

127 Patients with history of paroxysmal atrial fibrillation and indication for corona

128 blanking period after catheter ablation for paroxysmal atrial fibrillation but calls into question t

129 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation has demonstrated encourag

130 for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recru

131 However, paroxysmal atrial fibrillation is often asymptomatic and

132 ersus single tip wide area catheter ablation-paroxysmal atrial fibrillation is the first multinationa

133 for atrial fibrillation and represented with paroxysmal atrial fibrillation or atrial tachycardia und

134 In patients with drug-refractory paroxysmal atrial fibrillation or short-standing persist

135 This study includes the first 200 paroxysmal atrial fibrillation patients treated with the

136 before radiofrequency catheter ablation for paroxysmal atrial fibrillation significantly reduces the

137 dergoing radiofrequency catheter ablation of paroxysmal atrial fibrillation to receive remote IPC or

138 A total of 401 patients with paroxysmal atrial fibrillation undergoing pulmonary vein

139 Forty patients with paroxysmal atrial fibrillation underwent mandatory repea

140 ive patients (61+/-8 years old, 41 men) with paroxysmal atrial fibrillation underwent PVI using Carto

141 ke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation was common.

142 patients with symptomatic, drug-refractory, paroxysmal atrial fibrillation were enrolled in a prospe

143 Patients with paroxysmal atrial fibrillation were randomized to MEA (6

144 iofrequency energy delivery in patients with paroxysmal atrial fibrillation who undergo PVI and leads

145 e treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no signifi

146 pain syndrome, hypertension, and refractory paroxysmal atrial fibrillation, for which she had underg

147 ated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ovale, ao

148 In 20 patients with paroxysmal atrial fibrillation, synchronized high freque

149 In patients treated for paroxysmal atrial fibrillation, the pulmonary vein (PV)

150 is study, in patients undergoing ablation of paroxysmal atrial fibrillation, was to: (1) identify fac

151 inferiority study included 140 patients with paroxysmal atrial fibrillation, which was refractory to

152 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

153 ssociated with postblanking AT recurrence in paroxysmal atrial fibrillation.

154 al-time CF in the treatment of patients with paroxysmal atrial fibrillation.

155 ersus RF ablation for treating patients with paroxysmal atrial fibrillation.

156 pulmonary vein isolation in 46 patients with paroxysmal atrial fibrillation.

157 abbreviated QT interval (200 ms) on ECG and paroxysmal atrial fibrillation.

158 prevalent approach for catheter ablation of paroxysmal atrial fibrillation.

159 and simple pulmonary vein isolation to treat paroxysmal atrial fibrillation.

160 er ablation as treatment for drug-refractory paroxysmal atrial fibrillation.

161 in symptomatic patients with drug-refractory paroxysmal atrial fibrillation.

162 hepatic failure (3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%),

163 ominantly inherited disease characterized by paroxysmal attacks of ataxia and nystagmus.

164 Sixty subjects (age 60+/-10 years; 87% paroxysmal; CHADS2 score, 0.6+/-0.7) undergoing AF ablat

165 Further, the paroxysmal character, nocturnal pattern, and spontaneous

166 mbination-known as infantile convulsions and paroxysmal choreoathetosis (ICCA)-are related autosomal

167 rely presents with the classical symptoms of paroxysmal cough, whooping, apnea, and cyanosis.

168 es, presence of cough >/=14 days (20.5%) and paroxysmal coughing spells (33.3%) at diagnosis were unc

169 caling transformed asynchronous spiking into paroxysmal discharges.

170 ause for a wide and yet evolving spectrum of paroxysmal diseases.

171 ss of brain disorders that usually result in paroxysmal disorders, although their role in other neuro

172 d in an autosomal dominant fashion and cause paroxysmal disturbances of neurological function, althou

173 Paroxysmal dizziness spells (PDS), a unique LGI1-IgG acc

174 , peripheral manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1-IgG.

175 dysfunction is a rare disorder that leads to paroxysmal dizziness, fatigue, and syncope because of a

176 Paroxysmal dyskinesia can be subdivided into three clini

177 studies have been carried out on each of the paroxysmal dyskinesia genes, to date there has been no l

178 wo of PNKD) in a series of 145 families with paroxysmal dyskinesias as well as in a series of 53 pati

179 ng group of episodic movement disorders, the paroxysmal dyskinesias, and study of the causative genes

180 weeks) or late (>6 weeks after ablation) and paroxysmal (either spontaneous conversion or treated wit

181 st, independently of any stimulus and of any paroxysmal electroencephalographic activity.

182 ansition of normal physiological function to paroxysmal epileptic activity.

183 ve of 16 patients developed additional brief paroxysmal episodes in puberty, either dystonic/dyskinet

184 Seizures are paroxysmal events in which increased neuronal activity i

185 patient diary to record motor and non-motor paroxysmal events.

186 l kinesigenic dyskinesia or choreoathetosis, paroxysmal exercise-induced dyskinesia, and paroxysmal n

187 syndromes such as erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD).

188 ted with inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD).

189 Inherited "paroxysmal extreme pain disorder" (PEPD) differs in its

190 syndromes such as inherited erythromelalgia, paroxysmal extreme pain disorder, and small-fibre neurop

191 pain (CIP); (2) primary erythromelalgia; (3) paroxysmal extreme pain disorder; (4) febrile seizures a

192 ion in which trigeminal stimulation triggers paroxysmal facial pain, affects defensive peripersonal s

193 progressive condition, occurring first in a paroxysmal form, then in persistent, and then long-stand

194 (>/=7 consecutive days of AF >/=23 hours/d), paroxysmal (>/=1 day with AF >/=6 hours), or no/little A

195 8; persistent, HR, 3.60; 95% CI, 1.10-11.78; paroxysmal, HR, 2.88; 95% CI, 1.37-6.05).

196 esections, and a GluN2C/D antagonist reduces paroxysmal hyperexcitability.

197 h a basal brain hyperexcitability results in paroxysmal hypersynchronous neuronal discharges.

198 Initial recurrence was paroxysmal in 169 patients (76%) and persistent in 52 pa

199 CHA(2)DS(2)-VASC score of 4.5+/-1.2 and was paroxysmal in 26 (25.0%), persistent in 8 (7.7%), and pe

200 ears, the predominant arrhythmia pattern was paroxysmal in 62.3%, persistent in 28.2%, and permanent

201 Postrandomization AF/AT, which remained paroxysmal in 69.5%, did not reduce biventricular pacing

202 amilial infantile epilepsy (41.7%; n = 602), paroxysmal kinesigenic dyskinesia (38.7%; n = 560) and i

203 Paroxysmal kinesigenic dyskinesia (PKD) is characterized

204 Benign familial infantile seizures (BFIS), paroxysmal kinesigenic dyskinesia (PKD), and their combi

205 be subdivided into three clinical syndromes: paroxysmal kinesigenic dyskinesia or choreoathetosis, pa

206 x patients with 16p11.2 microdeletions and a paroxysmal kinesigenic dyskinesia phenotype have been re

207 nfantile convulsions and choreoathetosis and paroxysmal kinesigenic dyskinesia, confirming a common d

208 ssociated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesi

209 ), PRRT2 has been identified as the cause of paroxysmal kinesigenic dystonia and other genes, such as

210 clinical triad of epilepsy, dysarthria, and paroxysmal kinesigenic dystonia, and a high titer of Cas

211 Most atrial fibrillation was paroxysmal; less than 2% of admissions were always in at

212 e 21 105 patients were categorized as having paroxysmal (<7 days duration), persistent (>/=7 days but

213 UT1-DS experienced a mean of 30.8 (+/- 27.7) paroxysmal manifestations (52% motor events) at baseline

214 a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioener

215 After withdrawal, paroxysmal manifestations recurred with a mean of 24.2 (

216 GLUT1-DS (7-47 years old) with non-epileptic paroxysmal manifestations.

217 f 219 AF patients referred for ablation (59% paroxysmal, mean CHA2DS2VASc score 1.7 +/- 1.4) were enr

218 In addition, the nonepileptic paroxysmal movement disorder hyperekplexia has not previ

219 In patients with paroxysmal movement disorders 68 families had mutations

220 n various regions of the brain, resulting in paroxysmal movement disorders and seizure phenotypes.

221 The investigation of paroxysmal movement disorders should always include the

222 al syndromes of infancy, including epilepsy, paroxysmal movement disorders, and migraine.

223 s the phenotype-genotype overlap among these paroxysmal movement disorders.

224 Samples from 660 patients with paroxysmal (n = 370) or persistent AF (n = 290) were gen

225 ts, 61%; 64.0+/-10.0 years) with symptomatic paroxysmal (n=345; 42%) or persistent atrial fibrillatio

226 during (induced) AF in 10 patients with AF (paroxysmal: n=3; persistent: n=4; and longstanding persi

227 d interictal function are unaffected in many paroxysmal neurological channelopathies, possibly explai

228 ating, hemiplegic episodes; seizures and non-paroxysmal neurological features also occur.

229 6; 95% confidence interval [CI], 1.30-2.12), paroxysmal nocturnal dyspnea (odds ratio 1.95; 95% CI, 1

230 among self-reported PE, 2-pillow orthopnea, paroxysmal nocturnal dyspnea, left and right ventricular

231 cluding age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.

232 5 monoclonal antibody (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical h

233 predisposes individuals to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical h

234 , has been shown to prevent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve qu

235 To ascertain the genetic basis of a paroxysmal nocturnal hemoglobinuria (PNH) case without s

236 Paroxysmal nocturnal hemoglobinuria (PNH) cells are susc

237 Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder

238 Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalign

239 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone

240 Paroxysmal nocturnal hemoglobinuria (PNH) is characteriz

241 Paroxysmal nocturnal hemoglobinuria (PNH) is characteriz

242 he mechanism of bone marrow failure (BMF) in paroxysmal nocturnal hemoglobinuria (PNH) is not yet kno

243 vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on ec

244 ate that the erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) undergoing ecu

245 lood, Krawitz et al report on a patient with paroxysmal nocturnal hemoglobinuria (PNH) who does not h

246 The clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but li

247 In paroxysmal nocturnal hemoglobinuria (PNH), hematopoietic

248 progenitor cells (HSPCs) from patients with paroxysmal nocturnal hemoglobinuria (PNH).

249 ring work on hemolytic disorders, especially paroxysmal nocturnal hemoglobinuria (PNH).

250 ctivation on erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH); the authors d

251 mAb approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolyt

252 from other TMAs based on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensi

253 ease we demonstrated that FB28.4.2 protected paroxysmal nocturnal hemoglobinuria erythrocytes from co

254 tients with chronic hemolysis suffering from paroxysmal nocturnal hemoglobinuria in which the acquire

255 a 5-fold-enhanced complement regulation on a paroxysmal nocturnal hemoglobinuria patient's erythrocyt

256 ically relevant AP-mediated disease model of paroxysmal nocturnal hemoglobinuria, mini-FH largely out

257 omide-treated erythrocytes that recapitulate paroxysmal nocturnal hemoglobinuria, PspCN enhanced prot

258 esistance in a small number of patients with paroxysmal nocturnal hemoglobinuria.

259 val = 1.06-1.13), which is intronic to PNKD (paroxysmal non-kinesigenic dyskinesia) and TMBIM1 (trans

260 including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia a

261 paroxysmal exercise-induced dyskinesia, and paroxysmal non-kinesigenic dyskinesia.

262 Paroxysmal nonkinesigenic dyskinesia (PNKD) is an autoso

263 trial tissue was obtained from patients with paroxysmal or chronic AF and from control subjects in si

264 Fifty-three patients with symptomatic paroxysmal or persistent AF and without significant valv

265 Patients were classified as having paroxysmal or persistent AF by physicians at baseline in

266 ation, and oxidative stress in patients with paroxysmal or persistent AF not receiving conventional a

267 y and defibrillator implant and a history of paroxysmal or persistent AF were eligible.

268 l-arm study in 337 patients with symptomatic paroxysmal or persistent AF within 6 months of enrollmen

269 In 178 patients with paroxysmal or persistent AF, LA voltage maps were create

270 from AF/atrial tachycardia in patients with paroxysmal or persistent AF.

271 statistically different whether patients had paroxysmal or persistent AF.

272 erica and 4.5 million in European Union have paroxysmal or persistent atrial fibrillation.

273 nced the clinical decision to classify AF as paroxysmal or persistent.

274 ous leiomyomas can be associated with severe paroxysmal pain in which nerve conduction may have a key

275 enetic pain disorders that range from severe paroxysmal pain to a congenital inability to sense pain.

276 ngenital heart disease, with a predominantly paroxysmal pattern.

277 nch block, Left atrium >/=47 mm, Type of AF [paroxysmal, persistent or long-standing persistent], and

278 investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2

279 Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aor

280 n symptoms, the type of atrial fibrillation (paroxysmal, persistent, or long-standing persistent), pa

281 for scores >/=2, regardless of whether AF is paroxysmal, persistent, or permanent.

282 bodies were simultaneously tapped during the paroxysmal phase of this eruption.

283 additional 15 (10.0%) patients regressed to paroxysmal recurrences only.

284 s of all three genes, but around half of our paroxysmal series remain genetically undefined implying

285 The unifying term for the syndrome-paroxysmal sympathetic hyperactivity (PSH)-and clear dia

286 as the single causative gene for a group of paroxysmal syndromes of infancy, including epilepsy, par

287 The fast and frequent progression from paroxysmal to (long-standing) persistent or permanent AF

288 trial tachyarrhythmia and (2) progression of paroxysmal to (long-standing) persistent/permanent AF du

289 he mechanisms underlying the transition from paroxysmal to persistent atrial fibrillation (AF).

290 progression of atrial fibrillation (AF) from paroxysmal to persistent forms remains a major clinical

291 DF increased progressively during the paroxysmal-to-persistent AF transition and stabilized wh

292 childhood periodic syndromes include benign paroxysmal torticollis, benign paroxysmal vertigo, abdom

293 tremor, tardive tremor and rabbit syndrome, paroxysmal tremors (hereditary chin tremor, bilateral hi

294 Ninety consecutive AF patients (53% paroxysmal) undergoing radiofrequency ablation were recr

295 d postcontrast ventricular T1 time, AF type (paroxysmal versus persistent), AF duration, and body mas

296 Patients experiencing paroxysmal (versus persistent) initial recurrence were m

297 nclude benign paroxysmal torticollis, benign paroxysmal vertigo, abdominal migraine, and cyclic vomit

298 ersistent, p = 0.59), and 41 (46%) controls (paroxysmal vs. controls and persistent vs. controls, p <

299 This association was independent of AF type (paroxysmal vs. persistent).

300 paroxysmal AF, 83 (92%) with persistent AF (paroxysmal vs. persistent, p = 0.59), and 41 (46%) contr